One day after closing the Actavis Generics acquisition, Teva also acquired Allergan's Anda Inc., the 4th-largest U.S. distributor of generic pharmaceuticals, for $500M cash. Strategic complement to Actavis generics manufacturing, providing direct distribution to U.S. pharmacies and providers.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Assessment window: 5yr post-close.
Key facts
AnnouncedAug 03, 2016
ClosedAug 03, 2016
Deal value$500M
Deal typeAsset Purchase
Therapeutic areaN/A (distribution)
IndicationsN/A (distribution)
Key assetsAnda Inc. (4th-largest U.S. generic pharmaceuticals distributor)